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A Ab bs st tr ra ac ct t
Hereditary non polyposis colorectal cancer (HNPCC) is characterized by the presence of early onset colorectal
cancer and other epithelial malignancies. The genetic basis of HNPCC is a deficiency in DNA mismatch repair,
which manifests itself as DNA microsatellite instability in tumours. There are four genes involved in DNA
mismatch repair that have been linked to HNPCC; these include hMSH2, hMLH1, hMSH6 and hPMS2. 
Of these four genes hMLH1 and hMSH2 account for the majority of families diagnosed with the disease.
Notwithstanding, up to 40 percent of families do not appear to harbour a change in either hMSH2 or hMLH1
that can be detected using standard screening procedures such as direct DNA sequencing or a variety of
methods all based on a heteroduplex analysis. 
In this report we have screened a series of 118 probands that all have the clinical diagnosis of HNPCC for
medium to large deletions by the Multiplex Ligation-Dependent Probe Amplification assay (MLPA) to determine
the frequency of this type of mutation. The results indicate that a significant proportion of Australian HNPCC
patients harbour deletion or duplication mutations primarily in hMSH2 but also in hMLH1. 
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I In nt tr ro od du uc ct ti io on n   
Hereditary non polyposis colorectal cancer (HNPCC;
MIM 120435 and 120436) is an autosomal dominantly
inherited  disorder  that  predisposes  males  to 
an approximate colorectal cancer risk of 80% by 70 years
of age and females to a 40% risk of bowel cancer and
a 40% risk of endometrial cancer by the same age [1].
The genetic basis of HNPCC has been linked to errors
in  DNA  mismatch  repair  [2-5],  which  leaves
a characteristic tumour signature of DNA microsatellite
instability (MSI) that can be used as a surrogate marker
for this syndrome [6, 7]. 
At least four genes have been associated with
DNA mismatch repair and HNPCC and are hMSH2,
hMLH1,  hMSH6  and  hPMS2;  for  review  see
Papadopoulos and Lindblom [8]. Both hMSH2 and
hMLH1 account for somewhere between 50% and
60% of all families that adhere to the Amsterdam
Criteria (3 relatives with colorectal cancer (CRC); one
must be a first degree relative of the other two; cross
at least two generations; CRC must be diagnosed in
one relative under the age of 50 years and familial
adenomatous polyposis (FAP) must be excluded).
Somewhere between 2% and 20% of HNPCC families
defined by the Bethesda Criteria (excluding the
Amsterdam Criteria families) are associated with
mutations in these two genes [9-12]. The contribution
of hPMS2 and hMSH6 remains undefined, however,
on current evidence both hPMS2 and hMSH6 appearH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 44
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to account for approximately 5% of all HNPCC
families [13, 14]. 
The remaining 30-40% of Amsterdam Criteria
families  that  do  not  evidently  harbour  germline
mutations in the genes described either contain exonic
or whole gene deletions, cryptic alterations within their
coding regions, harbour changes in promoter/enhancer
regions  or  are  due  to  other  genes  that  await
identification [8]. The diagnosis of HNPCC families
remains problematic for a variety of reasons despite
knowledge about the genetic basis of the disease. 
The majority of mutations identified to date are
determined by genetic amplification strategies using the
polymerase chain reaction and thereafter, subsequent
analyses of the amplified product. This strategy has been
extremely valuable in identifying a large number of
mutations that can be clearly associated with disease
development. This approach, however, does not identify
inframe deletions that potentially remove whole exons
or the entire gene nor does it recognise duplications
that are capable of either introducing premature stop
codons or inserting transcribable coding sequence that
culminates in the insertion of nonsense peptide which
alters the functional properties of the protein. 
Using  a new  approach,  known  as  multiplex
ligation-dependent probe amplification (MLPA), deletion
changes can now readily be identified [15]. In this
report we have screened 118 probands who either
came from families that adhered to the Amsterdam or
Bethesda criteria for whole gene or exon deletions in
hMLH1 and hMSH2. Our results indicate that hMSH2
deletions are much more frequent in the Australian
population compared to hMLH1 deletions and that
MLPA is a useful aid in identifying smaller deletions that
occur in the proximity of the splice donor and acceptor
sites within hMSH2 and hMLH1. 
M Ma at te er ri ia al ls s   a an nd d   m me et th ho od ds s
P Pa at ti ie en nt ts s  a an nd d  s sa am mp pl le es s
All patients enrolled in this study have signed 
an informed consent document for genetic testing. 
The patients were from the State of New South Wales
or Western Australia, which has a total population of
approximately 9 million inhabitants. The centre where
the genetic testing was undertaken is a statewide service,
which also includes the Australian Capitol Territory. 
Patients selected for MLPA testing had been previously
diagnosed with cancer and had tested negative for point
mutations in hMLH1 or hMSH2 by DGGE or DHPLC
analysis. The majority of patients had obtained a positive
result for immunohistochemistry staining (i.e. displayed
absence of staining for either hMSH2 or hMLH1) and
were considered to be prime candidates to harbour
deletions within the respective gene. All families fulfilled
the diagnostic criteria of HNPCC by adhering to either
the Amsterdam 1 or 2 Criteria. 
D DN NA A  e ex xt tr ra ac ct ti io on n
All experiments were performed on genomic DNA
extracted from blood lymphocytes. DNA was isolated
from whole blood using the method described by Miller
et al [16] (1988) without modification. 
M ML LP PA A  r re ea ac ct ti io on n
A Multiplex Ligation-Dependent Probe Amplification
(MLPA) kit was obtained from MRC-Holland, Amsterdam,
the Netherlands. The MLPA method was developed by
Schouten  et  al  [15]  and  uses  a probe  mixture
containing16 probe pairs for hMSH2 and 19 probe pairs
for hMLH1 plus 7 control probe pairs. Initially 250 ng of
genomic DNA in 5 µl of TE was heated to 95
oC for
5 minutes and allowed to cool to 25
oC before addition
of the hMLH1 and hMSH2 probe mixture and buffer. 
The solution was reheated to 95
oC for 5 minutes followed
by  overnight  hybridisation  of  the  probe  at  60
oC. 
The mixture was cooled to 54
oC before DNA ligase and
buffer were added, followed by ligation at 54
oC for 15
minutes and inactivation of the ligase at 98
oC for
5 minutes. The ligation products were then amplified with
one unlabelled and one FAM-labelled primer using the
thermal cycling conditions advised by the manufacturer.
Following amplification, 0.75 µl of the PCR reaction,
0.75 µl of deionised water, 0.5 µl of an internal standard
(TAMRA-500) and 12 µl of deionised formamide were
mixed and incubated at 94
oC for 2 minutes. The samples
were then analysed on an Applied Biosystems 310
capillary sequencer with a 47-cm capillary and POP4
Genescan polymer. Data for the peak area were exported
to an Excel spreadsheet. All peak areas were normalised
by dividing each peak area by the combined peak areas
of all peaks in that lane. The normalised peak area was
then divided by the average normalised peak area of that
probe amplification product of all samples. Deletion 
of an exon for an allele is indicated by the reduction 
in a relative peak area for that probe amplification
product  of  30%,  while  duplication  is  indicated  by 
an increase in the peak area by 30%. 
D DN NA A  s se eq qu ue en nc ci in ng g
All single exon deletions were subject to DNA
sequencing to determine whether mutations occurredH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 45
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within  the  MLPA  probe  binding  regions,  thereby
presenting  as  an  apparent  exon  deletion.  DNA
sequencing was performed on a semi-automated
sequencing unit (model 310, Perkin-Elmer Applied
Biosystems Division, Foster City, CA) according to the
manufacturer’s instructions. 
R Re es su ul lt ts s
The majority of patients enrolled in this study had
had their tumours assessed for the presence or absence
of hMLH1 or hMSH2 and this information was used
as a guide to examine in detail which gene was most
likely to harbour a deletion or duplication. In those
instances where no knowledge was available about
the offending DNA mismatch repair gene then both
genes were interrogated with equal emphasis. 
From a total number of patients 18 index cases were
identified as having either a deletion or duplication in
hMSH2 or hMLH1. By far the greatest proportion of
confirmed exonic deletions (11) were identified in
hMSH2 (~61%) with only 2 exonic deletions being
identified in hMLH1 (~11%). Two duplications were
observed, one in hMSH2 and the other in hMLH1. 
Two apparent exonic deletions were also identified
by MLPA, which were due to a 2 base pair deletion
(1706-1707delAA) in hMSH2 and a 5 base pair
deletion (728-732delATGGT) in hMLH1, respectively.
These two changes occurred within the annealing sites
of the respective probes used for the assay. A third
potential deletion was observed in exon 16 of hMSH2
which could not be readily confirmed by virtue of there
being no easily identifiable method of determining the
3’ end of the deletion. Similar to the other two
apparent deletions a mutation was identified at position
2635, which was a substitution (C>G) that was within
the annealing site of exon 16 MPLA probe. 
Two duplications were identified, one in hMSH2
encompassing  exons  9-11  and  one  in  hMLH1
involving exons 4-6. Both of these changes were
presumed to disrupt the coding sequence by the
introduction of extraneous DNA. 
The changes identified in hMSH2 include one
whole  gene  deletion,  two  probands  with  exon
8 deleted, eight probands who harboured unique
deletions (see Table 1) and one patient that according
to MLPA had an exon 15 deletion. This deletion could
not be easily confirmed by an alternative method since
it occurs in the most 3’ exon of MSH2 and the
presumed breakpoint was not readily identifiable. 
The  two  remaining  exonic  deletions  in  hMLH1
included a deletion of exons 1 and 2 in one patient and
a deletion of exons 7 to 11 in a second unrelated patient. 
The disease characteristics of the patients harbouring
deletion mutations are shown in Table 1. The majority
of patients (83%) were diagnosed with colorectal cancer
under the age of 50 years and there were three patients
diagnosed with extra-colonic disease (two endometrial
cancers  and  one  ampulla  of  Vater  carcinoma). 
The family histories of disease were similar to that
expected  from  HNPCC  and  the  average  age  of
confirmed colorectal cancer was 44.8 years, which was
not significantly different to patients diagnosed with
other types of mutation in either hMSH2 or hMLH1 [17].
There were 101 cases of cancer reported in the families
of which 93 could be accurately identified. From the
93 reported cancer cases there were 65 cases of
colorectal cancer, 11 cancers of the reproductive tract
(both endometrial and ovarian cancers), 6 breast
cancer cases, of which four occurred at an unusually
early age and an assortment of unusual cancers that
have been found to be over-represented in HNPCC
families, including cancers of the central nervous system,
bile duct, stomach and kidney. 
D Di is sc cu us ss si io on n
The  identification  of  deletion  mutations  has
traditionally been difficult as it entailed the use of
Southern Blotting. Since the introduction of the multiplex
ligation-dependent  probe  amplification  assay  the
identification of deletion and duplication mutations has
become considerably easier. Accurate estimates of the
frequency of whole exon deletions or duplications in
HNPCC can now be addressed and in our experience
we believe that these types of mutation may account for
up to 15% of all mutations identified in the Australian
HNPCC population. In the population used in this report
exonic deletions or duplications of hMSH2 occurred with
a significantly greater frequency compared to hMLH1
which is in agreement with the findings of Gille et al [18],
Taylor et al [19], Charbonnier et al [20] and Bunyan et
al  2004  [21]  who  identified  primarily  hMSH2
deletion/duplication mutations. 
The  MLPA  assay  appears  to  be  an  extremely
valuable screening tool prior to a more extensive
mutation analysis as it not only identifies exonic
deletions/duplications but is also capable of identifying
point mutations that lie in the region of probe binding
or ligation. When point mutations occur within these
regions the resulting dosage appears as an apparent
loss of the respective exon. In our experience, if theH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 46
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T Ta ab bl le e   1 1. .   D Di is se ea as se e   c ch ha ar ra ac ct te er ri is st ti ic cs s   o of f   t th he e   1 18 8   f fa am mi il li ie es s   t te es st te ed d   b by y   M ML LP PA A
F Fa am mi il ly y    C CR RC C   Y Y/ /N N    O Ot th he er r   c ca an nc ce er rs s   Y Y/ /N N M Ma al le e/ / A Am ms st te er rd da am m A Am ms st te er rd da am m
n nu um mb be er r ( (a ag ge e   i in n   y ye ea ar rs s) ) ( (t ty yp pe e   a an nd d   a ag ge e) ) F Fe em ma al le e I I I II I B Be et th he es sd da a h hM MS SH H2 2 h hM ML LH H1 1
ex 16 Intronic 
substitution at
splice site
1 Y (49) N F Y N N position –2635-3 C>G
2 Y (47) N M N N Y ex 1-2 del
Apparent ex 11 del
due to 1706-1707
delAA (Stop at codon 570)
3 N Y (Ampulla Ca 52) F N Y N exs 2-12 del
4 Y (46, died 50) N F N N N (whole gene)
5 N Y (Endometrial >40) F Y Y Y exs 7-8 del
Apparent ex 9del 
due to 728-732del
ATGGT (codon 243 
-> Stop at codon 305
6 Y (50) N F N N N
7 Y (43,45) N M Y Y Y exs 9-14 del
8 Y (25, 48, 59) Y (Gastric 55) F Y Y Y ex 8 del
9 Y (Unknown) N M Y Y Y exs 1-2 del
10 Y (45, died 48) N F N Y Y exs 1-7
11 Y (>50) Y (Cervical Ca 38) F N N N exs 1-2
12 Y (18) N F N N N exs 11-16 
13 Y (45, 46) N M Y Y Y exs 5 
14 Y (41, 41) N M Y Y Y exs 7-11 del
15 Y N M exs 9&10 
16 N Y (Ovarian & Endo 46) F N Y Y ex 8 del
17 Y (34) N M Y Y Y exs 4 to 6 dup 
18 Y (70) N F N N N ex 9 to 11 dupl.
MLPA assay reveals a single exon deletion it should be
confirmed by sequencing the entire segment of DNA
including both primer-binding sites. By undertaking this
strategy we were able to identify small deletions in three
patients, which were all deemed to be causative as they
were predicted to interfere with exon splicing. 
When examining the family profiles of patients
harbouring deletion or duplication mutations against
families that harboured causative missense or nonsense
mutations  little  difference  between  the  disease
characteristics could be observed. In total there were
104 cancers identified in 18 families and the average
age of colorectal cancer diagnosis was 44.8 years
compared to that observed in our previous study
(45.77 years for hMSH2 mutation carriers and 47.16
for hMLH1 mutation carriers). All patients had a family
history of disease indicating that these changes were
not de novo. In addition to colorectal cancer, there was
an over-representation of endometrial cancer (13
cases), followed by CNS tumours (3 cases), renal tract
cancers (3) and a variety of other cancers present inH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 47
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2 or less patients. Interestingly, breast cancer was also
represented in this set of families with an average age
of  diagnosis  being  50  years.  Within  this  group,
however, there were two elderly patients; one case was
most likely to be a phenocopy (and could not be tested)
as she was 82 years of age and the other one who was
diagnosed with breast cancer at the age of 70 after
having been diagnosed with colorectal cancer at the
age of 63 years. All the other cases of breast cancer
were diagnosed under the age of 50 years. 
There were two duplications identified in this study,
one in hMSH2 and the other in hMLH1. There did not
appear to be any difference between those families
found to harbour duplications in either hMSH2 or
hMLH1 compared to families that harboured deletions
in either of these genes. The numbers of patients
precluded any statistical analysis. 
In summary, there does not appear to be any overall
difference in the disease profiles observed in families
that harbour exonic deletions compared to those that
have been shown to be associated with nonsense or
causative missense changes. MLPA appears to be an
extremely useful screening method that can identify up
to 15% of the mutations that occur in HNPCC families. 
R Re ef fe er re en nc ce es s
1. Watson P and Lynch HT. Extracolonic cancer in hereditary non
polyposis colorectal cancer. Cancer 1993; 71: 677-685. 
2. Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA,
Garber J, Kane M and Kolodner R. The human mutator gene
homolog MSH2 and its association with hereditary nonpolyposis
colon cancer. Cell 1993; 75: 1027-1038. 
3. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons
R, Peltomaki P , Sistonen P , Aaltonen LA, Nystrom-Lahti M, Guan
X-Y, Zhang J, Meltzer PS, Yu J-W, Kao F-T, Chen DJ, Cerosaletti RE,
Fournier K, Todds S, Lewis T, Leach RJ, Naylor SL, Weissenbach J,
Mecklin J-P , Jarvinen H, Petersen GM, Hamilton SR, Green J, Jass
J, Watson P , Lynch HT, Trent JM, de la Chapelle A, Kinzler KW and
Vogelstein  B.  Mutations  in  a mutS  homolog  in  hereditary
nonpolyposis colorectal cancer. Cell 1993; 75: 1215-1225. 
4. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe
MK, Kane M, Earabino C, Lipford J, Lindblom A, Tannergard P ,
Bollag RJ, Godwin AR, Ward DC, Nordenskjold M, Fishel R,
Kolodner R and Liskay RM. Mutation in the DNA mismatch repair
gene  homologue  hMLH1  is  associated  with  hereditary
nonpolyposis colon cancer. Nature 1994; 368: 258-261. 
5. Nicolaides NC, Papadopoulos N, Liu B, Wei Y-F, Carter KC,
Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser
GM, Adams MD, Venter JC, Dunlop MG, Hamilton SR, Petersen
GM, de la Chapelle A, Vogelstein B and Kinzler K. Mutations
of two PMS homologues in hereditary nonpolyposis colon cancer.
Nature 1994; 371: 75-80. 
6. Ionov Y, Peinado MA, Malkhosyan S, Shibata D and Perucho M.
Ubiquitous somatic mutations in simple repeated sequences
reveal a new mechanism for colonic carcinogenesis. Nature
1993; 363: 558-561. 
7. Thibodeau SN, Bren G and Schaid D. Microsatellite instability
in cancer of the proximal colon. Science 1993; 260: 816-819. 
8. Papadopoulos N and Lindblom A. Molecular basis of HNPCC:
mutations of MMR genes. Hum Mutat 1997; 10: 89-99. 
9. Buerstedde JM, Alday P , Torhorst J, Weber W, Muller H and Scott
R. Detection of new mutations in six out of 10 Swiss HNPCC
families by genomic sequencing of the hMSH2 and hMLH1
genes. J Med Genet 1995; 32: 909-912. 
10. Heinimann K, Scott RJ, Buerstedde J-M, Weber W, Siebold K,
Attenhofer M, Mueller HJ and Dobbie Z. Influence of selection
criteria  on  mutation  detection  in  patients  with  hereditary
nonpolyposis colorectal cancer. Cancer 1999; 86: 2512-2518. 
11. Wijnen JT, Vasen HFA, Meera Khan P , Zwindermann AH, van der
Klift H, Mulder A, Tops C, Moller P and Fodde R. Clinical findings
with implications for genetic testing in families with clustering of
colorectal cancer. New Engl J Med 1998; 339: 511-518. 
12. Syngal S, Fox EA, Li C, Dovidio M, Eng C, Kolodner RD and
Garber JE. Interpretation of genetic test results for hereditary
nonpolyposis  colorectal  cancer.  Implications  for  clinical
predisposition testing. JAMA 1999; 282: 247-253. 
13. Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT,
Watson P , Jass JR, Dunlop M, Wyllie A, Peltomaki P , de la
Chapelle A, Hamilton SR, Vogelstein B and Kinzler KW. Analysis
of mismatch repair genes in hereditary nonpolyposis colorectal
cancer patients. Nat Med 1996; 2: 169-174. 
14. Peltomaki P and Vasen HF . Mutations predisposing to hereditary
nonpolyposis  colorectal  cancer:  database  and  results  of
a collaborative study. The International Collaborative Group on
Hereditary Non Polyposis Colorectal Cancer. Gastroenterology
1997; 113: 1146-1158. 
15. Schouten JP , McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens
F and Pals G. Relative quantification of 40 nucleic acid
sequences by multiplex ligation-dependent probe amplification.
Nucleic Acids Res 2002; 30: e57. 
16. Miller SA, Dykes DD and Polesky H. A simple salting out
procedure for extracting DNA from human nucleated cells.
Nucleic Acids Res 1988; 53: 739. 
17. Scott RJ, McPhillips M, Meldrum CJ, Fitzgerald PE, Spigelman
AD, Tucker K, Kirk J and the Hunter Family Cancer Service.
Hereditary non polyposis colorectal cancer in 95 families:
differences between mutation positive and mutation negative
kindreds. Am J Hum Genet 2001; 68: 118-127. 
18. Gille, JJP , Hogervorst FBL, Pals G, Wijnen, JTH, van Schooten
RJ, Dommering CJ, Meijer GA, Craanen ME, Nederlof PM, de
Jong D, McElgunn CJ, Schouten, JP and Menko FH. Genomic
deletions of MSH2 and MLH1 in colorectal cancer families
detected by a novel mutation detection approach. Br J Cancer
2002; 87: 892-897. 
19. Taylor CF, Charlton RS, Burn J, Sheridan E and Taylor GR. Genomic
deletions in MSH2 or MLH1 are a frequent cause of hereditary
non-polyposis colorectal cancer: identification of novel and recurrent
deletions by MLPA. Hum Mutat 2003; 22: 428-433. 
20. Charbonnier F, Raux G, Wang Q, Drouot N, Cordier F, Limacher
JM, Saurin JC, Puisieux A, Olschwang S and Frebourg T.
Detection of exon deletions and duplications of the mismatch
repair genes in hereditary nonpolyposis colorectal cancer families
using multiplex polymerase chain reaction of short fluorescent
fragments. Cancer Res 2000; 60: 2760-2763. 
21. Bunyan DJ, Eccles DM, Sillibourne J, Wilkins E, Thomas NS,
Shea-Simonds J, Duncan PJ, Curtis CE, Robinson DO, Harvey
JF and Cross NC. Dosage analysis of cancer predisposition
genes by multiplex ligation-dependent probe amplification. 
Br J Cancer 2004; 91: 1155-1159. 